Trial Profile
A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2009
Price :
$35
*
At a glance
- Drugs Urelumab (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Biomarker
- 09 Sep 2009 Planned end date changed from 1 Jul 2009 to 1 Mar 2009 as reported by ClinicalTrials.gov.
- 09 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.